MacroGenics(MGNX)

Search documents
MacroGenics, Inc. Investors Reminder: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. Shareholders of Deadline in Securities Fraud Class Action Lawsuit
Prnewswire· 2024-09-07 15:15
RADNOR, Pa., Sept. 7, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. ("MacroGenics") (NASDAQ: MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the "Class Period" The lead plaintiff deadline is September 24, 2024. CONTACT KE ...
MacroGenics (MGNX) Crashed 28% After Pausing Phase 2 TAMARACK Study, Class Action Accuses Company of Misleading Investors Over Cancer Drug Trial – Hagens Berman
GlobeNewswire News Room· 2024-09-06 16:19
SAN FRANCISCO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now. Class Period: Mar. 7, 2024 – May 9, 2024 Lead Plaintiff Deadline: Sept. 24, 2024 Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916-0895 Class Action Lawsuit Against MacroGenics, Inc. (MGNX): On July 30, 2024, shares in beleaguered pharmaceutical company MacroGenics crashed after the company provided ...
Investors who lost money on MacroGenics, Inc.(MGNX) should contact The Gross Law Firm about pending Class Action - MGNX
Prnewswire· 2024-09-05 09:45
Core Viewpoint - MacroGenics, Inc. (NASDAQ: MGNX) is facing a class action lawsuit due to allegations of material misrepresentations regarding the safety data of its drug vobramitamab duocarmazine during the TAMARACK Phase 2 study, leading to a significant stock decline of 77.4% [1] Group 1 - The class period for the alleged misrepresentations is from March 7, 2024, to May 9, 2024 [1] - On May 9, 2024, it was revealed that the drug was significantly more dangerous than previously stated, resulting in a stock price drop of $11.36 per share [1] - Shareholders who purchased MGNX shares during the class period are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment [1][2] Group 2 - The deadline for shareholders to register for the class action is September 24, 2024 [2] - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2] - There is no cost or obligation for shareholders to participate in the case [2] Group 3 - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3]
ROSEN, A RANKED AND LEADING FIRM, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNX
GlobeNewswire News Room· 2024-09-04 22:47
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the "Class Period"), of the important September 24, 2024 lead plaintiff deadline. SO WHAT: If you purchased stock or sold puts of MacroGenics during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a cont ...
Kessler Topaz Meltzer & Check, LLP Notifies MacroGenics, Inc. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit
Prnewswire· 2024-09-01 14:45
RADNOR, Pa., Sept. 1, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. ("MacroGenics") (NASDAQ: MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the "Class Period" The lead plaintiff deadline is September 24, 2024. CONTACT KE ...
MacroGenics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 24, 2024 Deadline to file Lead Plaintiff Motion.
GlobeNewswire News Room· 2024-08-30 19:20
Core Viewpoint - A class-action lawsuit has been filed against MacroGenics, alleging that the company misled investors regarding the safety and effectiveness of its experimental cancer drug, vobra duo, particularly in relation to data from the Phase 2 TAMARACK clinical trial [3]. Group 1: Lawsuit Details - The class-action lawsuit represents investors who purchased MacroGenics securities between March 7, 2024, and May 9, 2024 [1]. - Investors have until September 24, 2024, to file a lead plaintiff motion [1]. - The lawsuit was filed in the Southern District of New York [3]. Group 2: Drug Performance and Market Reaction - Prior to the ASCO meeting in March 2024, MacroGenics promoted vobra duo as having promising results for patients with metastatic castration-resistant prostate cancer (mCRPC) [4]. - On April 3, 2024, interim data from the TAMARACK study indicated that reducing the dose and frequency of vobra duo improved safety and tolerability, resulting in a share price increase of $4.11, or approximately 30%, on April 4, 2024 [5]. - However, on May 10, 2024, the company reported five patient deaths in the study, leading to a significant share price drop of $11.36, or roughly 77%, on the same day, which prompted multiple analyst downgrades [6].
MacroGenics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights - MGNX
Prnewswire· 2024-08-29 09:45
Core Viewpoint - MacroGenics, Inc. (NASDAQ: MGNX) is facing a class action lawsuit due to allegations of material misrepresentations regarding the safety data of its drug vobramitamab duocarmazine during the TAMARACK Phase 2 study, leading to a significant stock decline of 77.4% [1] Group 1 - The class period for the lawsuit is from March 7, 2024, to May 9, 2024 [1] - On May 9, 2024, it was revealed that the drug was significantly more dangerous than previously stated, resulting in a stock price drop of $11.36 per share [1] - Shareholders are encouraged to register for the class action and can do so without any cost or obligation [2] Group 2 - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3]
ROSEN, LEADING INVESTOR COUNSEL, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNX
GlobeNewswire News Room· 2024-08-26 23:56
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the "Class Period"), of the important September 24, 2024 lead plaintiff deadline. SO WHAT: If you purchased stock or sold puts of MacroGenics during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a conti ...
MGNX Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against MacroGenics, Inc.
Prnewswire· 2024-08-26 23:15
RADNOR, Pa., Aug. 26, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. ("MacroGenics") (NASDAQ: MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the "Class Period" The lead plaintiff deadline is September 24, 2024. CONTACT KE ...
MGNX INVETOR ALERT: Kirby McInerney LLP Reminds MacroGenics, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit
GlobeNewswire News Room· 2024-08-23 21:37
NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of the September 26, 2024 to seek the role of lead plaintiff in a federal securities class action that has been filed on behalf of those who acquired MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX) securities during the period of March 7, 2024 to May 9, 2024, inclusive ("the Class Period"). [Click here to learn more about the class action] On May 9, 2024, MacroGenics announced in a press relea ...